APM
Aptorum A
–
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 138.21M; Volume: 62.26M; AvgVol 3m: 1.30M; Beta: –;
Cost estimate:
P/E: –; EPS: -0.64; EPS growth quarter/prev quarter: 71.00%;
EPS growth this year: -21.20%; EPS growth past 5 years: ;
EPS ttm: -0.54;
P/S: 152.57; P/B: 04.08; P/Cashflow: 21.29; P/FCF: ;
Sales: 870.00K; Sales growth quarter/prev quarter: 36.50%; Sales growth past 5 years: ;
Profitability:
Gross Margin: -38.00%; Profit Margin: ; Operating Margin: ;
ROA – return on assets: -54.00%; ROE – return on equity: -67.10%; LT Debt/Equity: 0.01; Total Debt/Equity: 0.01;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 37.66%; Insider Transactions:0.00%;
Institutional Ownership: 0.20%; Institutional Transactions: -26.07%;
Data update: 07/10/2020.